Skip to content
Medical Health Aged Care

Linnea SA of Switzerland and Universidade Estadual de Campinas (Unicamp) Brazil announce scientific partnership to promote cannabinoids research

Linnea 2 mins read

RIAZZINO, Switzerland, Feb. 06, 2024 (GLOBE NEWSWIRE) --  Linnea SA, a leading global Active Pharmaceutical Ingredients manufacturer with over 40 years of experience and a long-term presence in the Latam area, is pleased to announce the start of a strategic partnership with the Universidade Estadual de Campinas (UniCamp), a prestigious public research university in the state of São Paulo, Brazil. This important partnership aims to streamline and advance scientific development and research into cannabinoids.

The cannabinoid market in Latin America has been growing over the last years as a result of patients' demand for safe, reliable and effective therapy. The current cannabinoid delivery forms are often not aligned with the standards of quality typical of the pharmaceutical world and necessary to ensure the safety and the efficacy for patients.

As the demand for cannabinoid therapies rises, health authorities are gradually creating rules to protect consumers and help healthcare personnel to identify the best cannabinoid treatments.

To help accelerate this process, Linnea SA and Unicamp are now working together on the development of innovative cannabinoid-based products in alignment with current and future medical needs. Linnea SA and Unicamp believe promoting science through high-quality products can help people to receive better treatments.

Linnea SA currently sells their botanical nature derived APIs, including cannabinoids, to over 300 business partners in over 70 different countries worldwide. Linnea SA is proud to promote the best practices and are strongly committed to ongoing scientific research and development through global strategic partnerships.

Universidade Estadual de Campinas (Unicamp) is a well respected leading research university that is responsible for around 15% of Brazilian research and also produces more patents than any other research organization in Brazil.
You can find Linnea Cannabinoids online at www.linneacannabinoids.ch and get in contact at  https://www.linneacannabinoids.ch/contacts/

About Linnea Cannabinoids:
Linnea SA has been providing gold-standard botanical ingredients for use in the pharmaceutical, cosmetics and dietary supplement industries for over 40 years. Having expanded into the cannabis and cannabinoid industries in 2016, they helped pave the way in research, standardization and a pharmaceutical level of quality for this emerging global industry.

Media Contact:
Linnea SA - sales@linnea.ch


Primary Logo

More from this category

  • Biotechnology, Medical Health Aged Care
  • 09/12/2024
  • 15:45
Jane Morgan Management

NEXSEN Biotech Announces Pre-IPO Fundraising to Revolutionise Point-of-Care Diagnostics

Sydney, Australia – 9December, 2024 |NEXSEN Biotech Pty Ltd (“NEXSEN”), a pioneering diagnostics company, is excited to announce the launch of its pre-IPO fundraising round, targeting $2 million to $3 million. With a mission to improve global health outcomes, NEXSEN is set to deliver cutting-edge point-of-care diagnostic solutions that address critical unmet medical needs. At the heart of NEXSEN's innovation is StrepSure®, the world's first rapid diagnostic test for Group B Streptococcus (“GBS”). This revolutionary technology leverages advanced nanoparticle engineering and aptamer discovery, ensuring quick, accurate, and cost-effective diagnosis at the point of care. StrepSure® is poised to make life-saving…

  • Government Federal, Medical Health Aged Care
  • 09/12/2024
  • 12:14
Catholic Health Australia

CHA backs AMA push for greater access to out-of-hospital care

Catholic Health Australia supports the Australian Medical Association’s call for greater access to out-of-hospital care for patients, outlined in its position paper released today. “We have been calling for reform to out-of-hospital care for the past year and are pleased to see the sector unite around this issue,” said Catholic Health Australia CEO Jason Kara. “Treatments like chemotherapy, dialysis, wound care, palliative care and post-surgical rehab can be conducted safely at home with better outcomes - but millions of patients are missing out. “We urgently need reforms that allow patients and their doctors to choose where they receive their care,…

  • Medical Health Aged Care
  • 09/12/2024
  • 10:55
Monash University

Monash Expert: Australia’s growing arthritis burden

The number of people living with arthritis in Australia is projected to increase by a third by 2040, suggests a modelling study, published in The Lancet Rheumatology. The model projects about 5.4 million Australians will have arthritis in 2040, 1.3 million (31 per cent) more than the estimated number of cases for 2025. Annual health system spending on osteoarthritis – the most common type of arthritis, and rheumatoid arthritis, the most common type of inflammatory arthritis – is forecast to exceed AUD $11.9 billion by 2040, if current spending levels continue, estimated at AUD $2,100 per person with osteoarthritis and…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.